| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1182/BLOOD-2007-08-078139 |
| P698 | PubMed publication ID | 18467609 |
| P2093 | author name string | S. D. Nimer | |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 4841-4851 | |
| P577 | publication date | 2008-05-15 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Myelodysplastic syndromes | |
| P478 | volume | 111 |
| Q35423470 | 5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes. |
| Q37601778 | 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis |
| Q37549908 | 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. |
| Q33437345 | 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). |
| Q91899628 | A diagnosis of discernment: Identifying a novel ATRX mutation in myelodysplastic syndrome with acquired α-thalassemia |
| Q47099325 | A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts. |
| Q35143275 | A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes |
| Q34204750 | A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia |
| Q43688460 | Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia |
| Q39272984 | Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome |
| Q34179367 | Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics |
| Q34984094 | Acquired mutations in TET2 are common in myelodysplastic syndromes |
| Q55256343 | Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review. |
| Q92095724 | Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs |
| Q51815934 | Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. |
| Q33692856 | Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis |
| Q41101447 | An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614). |
| Q38588663 | Analysis of class I and II histone deacetylase gene expression in human leukemia |
| Q37207084 | Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion |
| Q85213650 | Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome |
| Q24634431 | Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia |
| Q43164242 | Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program |
| Q37632391 | Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia |
| Q34273735 | Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia |
| Q37295279 | Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group |
| Q33429792 | Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience |
| Q45928400 | Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. |
| Q92491398 | Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study |
| Q38757359 | Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells |
| Q34087088 | Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome. |
| Q40282393 | Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning |
| Q36141927 | Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. |
| Q33392205 | Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience |
| Q33999887 | Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction |
| Q26991974 | Deconstructing innate immune signaling in myelodysplastic syndromes |
| Q24599447 | Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na |
| Q50554973 | Disseminated adenovirus disease in immunocompromised patient successfully treated with oral ribavirin: a case report. |
| Q46110570 | Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms |
| Q36503074 | Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB. |
| Q35004935 | Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation |
| Q39675914 | Epigenetic alterations of p15(INK4B) and p16(INK4A) genes in pediatric primary myelodysplastic syndrome. |
| Q53817619 | Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. |
| Q37850456 | Epigenetic regulation in myelodysplastic syndromes: implications for therapy |
| Q37964702 | Epigenetic-based therapies in cancer: progress to date |
| Q37414694 | Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction |
| Q42708649 | Establishment of a xenograft model of human myelodysplastic syndromes |
| Q33657377 | Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. |
| Q33595649 | Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. |
| Q39095725 | Functional polymorphisms in the CD44 gene and acute myeloid leukemia cancer risk in a Chinese population |
| Q41192395 | Functional study of hENT1 on SKM-1 cell resistance to decitabine |
| Q37858877 | Gene expression profiling in MDS and AML: potential and future avenues. |
| Q90245162 | Genetic basis of myelodysplastic syndromes |
| Q42198272 | Haploinsufficiency of Apc leads to ineffective hematopoiesis |
| Q37810109 | Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes |
| Q37961859 | Histone methylation in myelodysplastic syndromes |
| Q34667051 | Hypomethylating agents and other novel strategies in myelodysplastic syndromes |
| Q24186276 | Hypomethylating agents for patients with myelodysplastic syndrome |
| Q24236549 | Hypomethylating agents for patients with myelodysplastic syndrome |
| Q88960735 | ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications |
| Q35011883 | Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype |
| Q35264063 | Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. |
| Q40789369 | Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes |
| Q64979584 | Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. |
| Q91664759 | Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry |
| Q50480672 | Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes. |
| Q39824884 | Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes |
| Q36779451 | Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo |
| Q42194645 | Karyotypic and fluorescent in situ hybridization study of the centromere of chromosome 7 in secondary myeloid neoplasms |
| Q35891637 | Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model |
| Q38844008 | L3MBTL1 deficiency directs the differentiation of human embryonic stem cells toward trophectoderm |
| Q35813255 | Large-vessel thrombosis in intestinal Behçet's disease complicated with myelodysplastic syndrome and trisomy 8. |
| Q42253318 | Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion |
| Q37512080 | Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice |
| Q39157705 | Loss of p300 accelerates MDS-associated leukemogenesis |
| Q36318158 | Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model |
| Q94325800 | Low dose cytarabine monotherapy for myelodysplastic syndromes |
| Q24234789 | Low dose cytarabine monotherapy for myelodysplastic syndromes |
| Q36611010 | MSI2 is required for maintaining activated myelodysplastic syndrome stem cells |
| Q64885639 | Management of myelodysplastic syndromes after failure of response to hypomethylating agents. |
| Q38175397 | Mesenchymal stem cells in immune-mediated bone marrow failure syndromes |
| Q37273157 | Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide |
| Q43683766 | Metabolism-related cytokine and hormone levels in the serum of patients with myelodysplastic syndromes |
| Q34006457 | Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome |
| Q53122486 | Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis. |
| Q35220370 | MicroRNA function in myeloid biology |
| Q49521797 | MicroRNA, an Antisense RNA, in Sensing Myeloid Malignancies |
| Q36864863 | MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice |
| Q35911998 | Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. |
| Q53272408 | Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations. |
| Q40214885 | Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia. |
| Q37974844 | Mutations in epigenetic regulators in myelodysplastic syndromes |
| Q35001132 | Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? |
| Q33387657 | Myelodysplastic syndrome in elderly patients: correlation of CBC with cytogenetic and FISH analysis |
| Q37204110 | Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report |
| Q99616799 | Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis |
| Q44325617 | Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification |
| Q37790694 | NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia |
| Q51725692 | Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine. |
| Q45088115 | Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value |
| Q43992058 | Non-infectious pulmonary complications of myelodysplastic syndromes and chronic myeloproliferative disorders |
| Q36309518 | Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2. |
| Q38640493 | Novel methods for studying normal and disordered erythropoiesis |
| Q41350670 | Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858 |
| Q38285652 | Nuclear Nox4-derived reactive oxygen species in myelodysplastic syndromes |
| Q37158530 | Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. |
| Q36877036 | Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure |
| Q53270403 | Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine. |
| Q35137424 | Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest |
| Q46729480 | Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study. |
| Q37059401 | Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure |
| Q34541057 | Pathogenic microRNA's in myeloid malignancies |
| Q45903583 | Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. |
| Q33399233 | Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system |
| Q52888395 | Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. |
| Q34198784 | Progeroid syndromes: models for stem cell aging? |
| Q33769072 | Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis |
| Q47124670 | Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions |
| Q38107912 | Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype. |
| Q42662727 | Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes |
| Q34707445 | Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice |
| Q40592382 | Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes. |
| Q36920394 | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M |
| Q33725731 | Ribosomal protein L23 negatively regulates cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndrome |
| Q91081522 | Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome |
| Q91430061 | S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes |
| Q35849733 | SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. |
| Q37685420 | SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis |
| Q39117707 | Selenium compounds induced ROS-dependent apoptosis in myelodysplasia cells. |
| Q46050808 | Serum erythropoietin at diagnosis in low grade myelodysplastic syndrome correlates with both red cell zinc protoporphyrin and serum lactic dehydrogenase (LDH) and may reflect severity of ineffective erythropoiesis |
| Q52659475 | Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation. |
| Q58865825 | Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival |
| Q37840934 | Standards and impact of hematopathology in myelodysplastic syndromes (MDS). |
| Q52560161 | Survey and evaluation of mutations in the human KLF1 transcription unit. |
| Q36814300 | TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances |
| Q91735717 | TET2 deficiency leads to stem cell factor-dependent clonal expansion of dysfunctional erythroid progenitors |
| Q57734311 | TET2 mutations in myelodysplasia and myeloid malignancies |
| Q37392696 | TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes |
| Q37218274 | TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients |
| Q37011627 | Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome |
| Q46082519 | Telomere shortening and chromosomal instability in myelodysplastic syndromes |
| Q37134517 | The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes |
| Q34520113 | The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores |
| Q91045747 | The functional mechanisms of mutations in myelodysplastic syndrome |
| Q40560744 | The next new target in leukemia: The embryonic stem cell gene SALL4. |
| Q59790119 | The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo |
| Q38353167 | Therapy-related myelodysplastic syndrome |
| Q24198060 | Thrombopoietin mimetics for patients with myelodysplastic syndromes |
| Q47550396 | Thrombopoietin mimetics for patients with myelodysplastic syndromes. |
| Q89777137 | Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis |
| Q33652652 | Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. |
| Q33707400 | Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study |
| Q39601934 | Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms |
| Q37407161 | Update on genetic and molecular markers associated with myelodysplastic syndromes. |
| Q37333623 | Upsides and downsides to polarity and asymmetric cell division in leukemia. |
| Q57818210 | Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome |
| Q38039381 | What's all the fuss about? facts and figures about bone marrow failure and conditions |
Search more.